SEC Comment Letter 0000000000-25-001186 to Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc.
Date: Feb. 4, 2025 · CIK: 0001736243 · Accession: 0000000000-25-001186
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284627
Letter
February 4, 2025 David P. Luci President, Chief Executive Officer and Director Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305 Re:Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed January 31, 2025 File No. 333-284627 Dear David P. Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ivan Blumenthal, Esq.
Show Raw Text
February 4, 2025
David P. Luci
President, Chief Executive Officer and Director
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305
Re:Acurx Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed January 31, 2025
File No. 333-284627
Dear David P. Luci:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ivan Blumenthal, Esq.